FDA has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla), also called T-DM1, to include adjuvant treatment in some women with early-stage HER2-positive breast cancer.
from Cancer Currents: An NCI Cancer Research Blog http://bit.ly/2M6nbdq